0H22 Stock Overview
A clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 33.80 |
| 52 Week High | SEK 49.00 |
| 52 Week Low | SEK 23.75 |
| Beta | -0.084 |
| 1 Month Change | 36.43% |
| 3 Month Change | 29.50% |
| 1 Year Change | 27.79% |
| 3 Year Change | -18.84% |
| 5 Year Change | n/a |
| Change since IPO | -94.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H22 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 7.3% | 5.1% | 0.9% |
| 1Y | 27.8% | -15.3% | 0.3% |
Return vs Industry: 0H22 exceeded the UK Biotechs industry which returned -11.8% over the past year.
Return vs Market: 0H22 exceeded the UK Market which returned 1.1% over the past year.
Price Volatility
| 0H22 volatility | |
|---|---|
| 0H22 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0H22's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0H22's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 118 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| 0H22 fundamental statistics | |
|---|---|
| Market cap | SEK 2.25b |
| Earnings (TTM) | -SEK 468.06m |
| Revenue (TTM) | SEK 60.80m |
37.0x
P/S Ratio-4.8x
P/E RatioIs 0H22 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H22 income statement (TTM) | |
|---|---|
| Revenue | SEK 60.80m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 60.80m |
| Other Expenses | SEK 528.87m |
| Earnings | -SEK 468.06m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 26, 2025
| Earnings per share (EPS) | -7.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -769.79% |
| Debt/Equity Ratio | 0% |
How did 0H22 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 17:00 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInvent International AB (publ) is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |